New pathways to renal damage: Role of ADMA in retarding renal disease progression

Journal of Nephrology

Volumn 23, Issue 4, 2010, Pages 377-386

  Ueda, Seiji ^a   Yamagishi, Sho Ichi ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Asymmetric dimethylarginine; CKD; CVD; Dimethylarginine dimethylaminohydrolase; Endothelial dysfunction; Nitric oxide

Indexed keywords

DIMETHYLARGININASE; N(G),N(G) DIMETHYLARGININE; AMIDASE; ARGININE; N,N-DIMETHYLARGININE;

AMINO ACID METABOLISM; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DEGRADATION; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; IN VIVO STUDY; KIDNEY INJURY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN METABOLISM; PROTEIN METHYLATION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; KIDNEY DISEASES; MOUSE; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

AMIDOHYDROLASES; ANIMALS; ARGININE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; KIDNEY DISEASES; MICE; PROTEINURIA;

EID: 77955434278     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
2. Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol. 2006;17:2112-2119.
3. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169. (Pubitemid 37337595)
4. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation. 1997;96:379-382.
5. Cooke JP. Dose ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037.
6. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157.
7. Ueda S, Yamagishi S, Kaida Y, Okuda S. Asymmetric dimethylarginine (ADMA) may be a missing link between chronic kidney disease (CKD) and cardiovascular disease (CVD). Nephrology. 2007;12:582-590.
8. Zoccali C. The endothelium as a target in renal diseases. J Nephrol. 2007;20:S39-S44.
9. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-1146. (Pubitemid 29120084)
10. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care. 2004;27:765-769. (Pubitemid 38280547)
11. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
12. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-2117.
13. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary event and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-2128.
14. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the Athero-Gene Study. Circ Res. 2005;97:e53-e59.
15. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
16. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002;13:170-176.
17. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006;70:781-787. (Pubitemid 44215355)
18. Kielstein JT, Martens-Lobenhoffer J, Vollmer S, Bode-Böger SM. L-Arginine, ADMA, SDMA, creatinine, MDRD formula: detour to renal function testing. J Nephrol. 2008;21:959-961.
19. Panichi V, Mantuano E, Paoletti S, et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol. 2008;21:38-44.
20. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002;13:490-496.
21. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005;16:2456-2461. (Pubitemid 41725064)
22. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005;16:2449-2455.
23. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:III27-III32.
24. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285-1295.
25. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489-509. (Pubitemid 27101848)
26. Matsuoka H. Endothelial dysfunction associated with oxidative stress in human. Diabetes Res Clin Pract. 2001;54:S65-S72.
27. Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol. 2000;35:71-75.
28. Boger RH. The pharmacodynamics of L-arginine. J Nutr. 2007;137:1650S-1655S.
29. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46:518-523.
30. Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006;47:42-50.
31. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
32. Cross JM, Donald A, Vallance P, Deanfield JE, Woolfson RG, MacAllister RJ. Hemodialysis improves endothelial function in humans. Nephrol Dial Transplant. 2001;16:1823-1829.
33. Hibbs JB Jr, Vavrin Z, Taintor RR. L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol. 1987;138:550-565. (Pubitemid 17002220)
34. MacAllister RJ, Whitley GS, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int. 1994;45:737-742.
35. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59:824-833.
36. Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol. 1995;269:H1522-H1527.
37. Segarra G, Medina P, Ballester RM, et al. Effects of some guanidino compounds on human cerebral arteries. Stroke. 1999;30:2206-2210.
38. Segarra G, Medina P, Vila JM, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens. 2001;14:1142-1148.
39. Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Regional and cardiac haemodynamic effects of NG,NG,dimethyl- L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol. 1993;110:1457-1464. (Pubitemid 23360978)
40. Jin JS, D'Alecy LG. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol. 1996;28:439-446.
41. Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int. 2001;59:1466-1472.
42. Pollock JS, Forstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A. 1991;88:10480-10484. (Pubitemid 21915859)
43. Jeserich M, Munzel T, Just H, Drexler H. Reduced plasma L-arginine in hypercholesterolaemia. Lancet. 1992;339:561.
44. Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2007;282:879-887.
45. Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592-1600.
46. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24:1682-1688.
47. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide. 1997;1:65-73. (Pubitemid 28078129)
48. Bode-Boger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17:1128-1134.
49. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-1459.
50. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87:99-105.
51. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med. 2005;10:S3-S9. (Pubitemid 43137262)
52. Lee J, Sayegh J, Daniel J, Clarke S, Bedford MT. PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem. 2005;280:32890-32896.
53. Cook JR, Lee JH, Yang ZH, et al. FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues. Biochem Biophys Res Commun. 2006;342:472-481.
54. Niu L, Lu F, Pei Y, Liu C, Cao X. Regulation of flowering time by the protein arginine methyltransferase AtPRMT10. EMBO Rep. 2007;8:1190-1195.
55. Scebba F, De Bastiani M, Bernacchia G, Andreucci A, Galli A, Pitto L. PRMT11: a new Arabidopsis MBD7 protein partner with arginine methyltransferase activity. Plant J. 2007;52:210-222.
56. Rawal N, Rajpurohit R, Paik WK, Kim S. Purification and characterization of S-adenosylmethionine-protein-arginine N-methyltransferase from rat liver. Biochem J. 1994;300:483-489.
57. Ghosh SK, Paik WK, Kim S. Purification and molecular identification of two protein methylase I from calf brain: myelin basic protein- and histone-specific enzyme. J Biol Chem. 1988;263:19024-19033.
58. Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol. 1998;61:65-131.
59. Spoto B, Parlongo RM, Parlongo G, Sgro' E, Zoccali C. The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. J Nephrol. 2007;20:554-559.
60. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension. 2003;42:985-990.
61. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG, NG-dimethyl- L-arginine to L-citrulline in rats. Biochem Biophys Res Commun. 1987;148:671-677.
62. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987-992.
63. MacAllister RJ, Fickling SA, Whitley GS, et al. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol. 1994;112:43-48.
64. G-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem. 1995;117:237-238.
65. G-dimethylarginine dimethylaminohydrolase. Eur J Biochem. 1998;258:863-868.
66. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J. 1999;343:209-214. (Pubitemid 29473897)
67. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13:198-203.
68. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;119:1533-1540.
69. Ueda S, Kato S, Matsuoka H, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res. 2003;92:226-233.
70. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99:3092-3095. (Pubitemid 29289071)
71. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol. 2006;17:2176-2183.
72. Zoccali C, Kielstein JT. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens. 2006;15:314-320.
73. G-dimethyl-arginine, N-mono-, di-, and trimethyllysine, and glucosylgalactosyl-, and galactosyl-δ-hydroxylysine from human urine. J Biol Chem. 1970;245:5751-5758.
74. G-dimethylarginine in the rabbit. Biochem J. 1976;154:179-184.
75. Fliser D, Kielstein JT, Haller H, Bode-Boger SM. Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Kidney Int Suppl. 2003;(84):S37-S40.
76. Tain YL, Freshour G, Dikalova A, Griendling KK, Baylis C. Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol. 2007;292:F1404-F1410.
77. Okubo K, Hayashi K, Wakino S, et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res. 2005;28:181-189.
78. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A. 2002;99:13527-13532. (Pubitemid 35215415)
79. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.
80. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15 Suppl 1:S77-S80. (Pubitemid 38018461)
81. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575.
82. Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol. 2005;45:525-532.
83. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62:339-345.
84. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylargine. J Am Coll Cardiol. 2005;46:1693-1701.
85. Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun. 2003;308:984-989.
86. Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer. 2002;87:673-680.
87. Jacobi J, Sydow K, von Degenfeld G, et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation. 2005;111:1431-1438.
88. Konishi H, Sydow K, Cooke JP. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol. 2007;49:1099-1105. (Pubitemid 46349507)
89. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
90. Dominiczak AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension. 1995;25:1202-1211.
91. Arnal J-F, Michel J-B, Harrison DG. Nitric oxide in the pathogenesis of hypertension. Curr Opin Nephrol Hypertens. 1995;4:182-188.
92. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-1459.
93. MacAllister R, Vallance P. Nitric oxide in essential and renal hypertension. J Am Soc Nephrol. 1994;5:1057-1065. (Pubitemid 24977082)
94. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, Una, and vasoactive hormones in healthy humans. Am J Physiol. 1996;270:F845-F851.
95. Ruilope LM, Lahera V, Rodicio JL, Romero JC. Participation of nitric oxide in the regulation of renal function: possible role in the genesis of arterial hypertension. J Hypertens. 1994;12:625-631. (Pubitemid 24211281)
96. Kielstein JT, Simmel S, Bode-Boger SM, et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res. 2004;27:143-147.
97. Matsuoka H, Itoh S, Kimoto M, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242-247.
98. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation. 2003;108:3042-3047.
99. Matsumoto Y, Ueda S, Yamagishi S, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol. 2007;18:1525-1533.
100. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest. 2005;35:622-626.
101. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172-177. (Pubitemid 38114135)
102. Kielstein JT, Bode-Böger SM, Frölich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, BP, and renal perfusion in elderly subjects. Circulation. 2003;107:1891-1895.
103. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418.
104. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969-975.
105. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol. 2006;17:2106-2111. (Pubitemid 44141899)
106. Arcos MI, Fujihara CK, Sesso A, et al. Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol. 2000;279:F1060-F1066.
107. Sharma M, McCarthy ET, Savin VJ, Lianos EA. Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int. 2005;68:2735-2744.
108. Yilmaz MI, Sonmez A, Saglam M, et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol. 2008;19:388-395.
109. Sharma M, Zou Z, Miura H, et al. ADMA injures glomerular filtration barrier: role of nitric oxide and superoxide. Am J Physiol Renal Physiol. 2009;296:F1386-F1395.
110. Shibata R, Ueda S, Yamagishi S, et al. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol Dial Transplant. 2009;24:1162-1169.
111. Marliss EB, Chevalier S, Gougeon R, et al. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia. 2006;49:351-359.
112. Yilmaz MI, Saglam M, Sonmez A, et al. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif. 2007;25:327-335.
113. Kielstein JT, Fliser D. Lowering asymmetric dimethylarginine: a new mechanism mediating the renoprotective effects of reninangiotensin system inhibitors in proteinuric patients? Blood Purif. 2007;25:324-326.
114. Tojo A, Welch WJ, Bremer V, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997;52:1593-1601.
115. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-252.
116. Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl. 1998;65:S74-S78. (Pubitemid 28204569)
117. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:17-25.
118. Kang DH, Nakagawa T, Feng L, et al. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol. 2002;161:239-248. (Pubitemid 34760789)
119. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: Part I: potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12:1434-1447.
120. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567-2578.